CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response

Avanzi, 2018, Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system, Cell Rep., 23, 2130, 10.1016/j.celrep.2018.04.051

Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588

Barbier, 2012, Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation, J. Hepatol., 57, 352, 10.1016/j.jhep.2012.03.023

Beatty, 2011, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, Science, 331, 1612, 10.1126/science.1198443

Beatty, 2013, A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, Clin. Cancer Res., 19, 6286, 10.1158/1078-0432.CCR-13-1320

Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol. Ther. Oncolytics, 3, 16011, 10.1038/mto.2016.11

Bossen, 2006, Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human, J. Biol. Chem., 281, 13964, 10.1074/jbc.M601553200

Bourgeois, 2002, A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory, Science, 297, 2060, 10.1126/science.1072615

Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat. Med., 9, 279, 10.1038/nm827

Brown, 1998, Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice, Nat. Med., 4, 1253, 10.1038/3233

van der Bruggen, 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254, 1643, 10.1126/science.1840703

Byrne, 2016, CD40 stimulation obviates innate sensors and drives T cell immunity in cancer, Cell Rep., 15, 2719, 10.1016/j.celrep.2016.05.058

Byrne, 2016, CSF-1R-dependent lethal hepatotoxicity when agonistic CD40 antibody is given before but not after chemotherapy, J. Immunol., 197, 179, 10.4049/jimmunol.1600146

Casamayor-Palleja, 1995, A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex, J. Exp. Med., 181, 1293, 10.1084/jem.181.4.1293

Castro, 2012, Gene immunotherapy of chronic lymphocytic leukemia: A phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule, Cancer Res., 72, 2937, 10.1158/0008-5472.CAN-11-3368

Caux, 1994, Activation of human dendritic cells through CD40 cross-linking, J. Exp. Med., 180, 1263, 10.1084/jem.180.4.1263

Cella, 1996, Brief definitive report ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation, J. Exp. Med., 184, 747, 10.1084/jem.184.2.747

Cheadle, 2010, Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered t cells, J. Immunol., 184, 1885, 10.4049/jimmunol.0901440

Chmielewski, 2011, IL-12 release by macrophages expressing chimeric antigen receptors can effectively restore T cell attacks on tumor cells that have shut down tumor antigen expression, Cancer Res., 71, 5697, 10.1158/0008-5472.CAN-11-0103

Curran, 2015, Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression, Mol. Ther., 23, 769, 10.1038/mt.2015.4

Davila, 2013, CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia, PLoS One, 8, e61338, 10.1371/journal.pone.0061338

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6, 224ra25, 10.1126/scitranslmed.3008226

Dicker, 2005, Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells, Blood, 105, 3193, 10.1182/blood-2003-10-3684

Dupage, 2012, Expression of tumour-specific antigens underlies cancer immunoediting, Nature, 482, 405, 10.1038/nature10803

Elgueta, 2009, Molecular mechanism and function of CD40/CD40L engagement in the immune system, Immunol. Rev., 229, 152, 10.1111/j.1600-065X.2009.00782.x

Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405

Garrone, 1995, Fas ligation induces apoptosis of CD40-activated human B lymphocytes, J. Exp. Med., 182, 1265, 10.1084/jem.182.5.1265

Giavridis, 2018, CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter, Nat. Med., 24, 731, 10.1038/s41591-018-0041-7

Gubin, 2014, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, 515, 577, 10.1038/nature13988

Guedan, 2018, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation, JCI Insight, 3, 10.1172/jci.insight.96976

Helft, 2015, GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells, Immunity, 42, 1197, 10.1016/j.immuni.2015.05.018

Hollmann, 2006, Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death, Cancer Res., 66, 3550, 10.1158/0008-5472.CAN-05-2498

Hu, 2017, Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18, Cell Rep., 20, 3025, 10.1016/j.celrep.2017.09.002

Klebanoff, 2016, Prospects for gene-engineered T cell immunotherapy for solid cancers, Nat. Med., 22, 26, 10.1038/nm.4015

Knorr, 2018, Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity, Proc. Natl. Acad. Sci. U S A, 115, 11048, 10.1073/pnas.1810566115

van Kooten, 1997, Functions of CD40 on B cells, dendritic cells and other cells, Curr. Opin. Immunol., 9, 330, 10.1016/S0952-7915(97)80078-7

Lee, 2003, CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment, J. Exp. Med., 198, 1759, 10.1084/jem.20031440

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Lee, 2009, Retroviral transduction of murine primary T lymphocytes, Methods Mol Biol., 506, 83, 10.1007/978-1-59745-409-4_7

Macatonia, 1995, Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells, J. Immunol., 154, 5071, 10.4049/jimmunol.154.10.5071

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N. Engl. J. Med., 378, 439, 10.1056/NEJMoa1709866

van Mierlo, 2002, CD40 stimulation leads to effective therapy of CD40− tumors through induction of strong systemic cytotoxic T lymphocyte immunity, Proc. Natl. Acad. Sci. U S A, 99, 5561, 10.1073/pnas.082107699

de Mingo Pulido, 2018, TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer, Cancer Cell, 33, 60, 10.1016/j.ccell.2017.11.019

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447

Ouaaz, 2002, Dendritic cell development and survival require distinct NF-κB subunits, Immunity, 16, 257, 10.1016/S1074-7613(02)00272-8

Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N. Engl. J. Med., 378, 449, 10.1056/NEJMoa1709919

Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood, 119, 4133, 10.1182/blood-2011-12-400044

Ranheim, 1993, Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal, J. Exp. Med., 177, 925, 10.1084/jem.177.4.925

Riviere, 1995, Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells, Proc. Natl. Acad. Sci., 92, 6733, 10.1073/pnas.92.15.6733

Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395

Salmon, 2016, Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition, Immunity, 44, 924, 10.1016/j.immuni.2016.03.012

Schoenberger, 1998, T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions, Nature, 393, 480, 10.1038/31002

Tong, 2003, Prospects for CD40-directed experimental therapy of human cancer, Cancer Gene Ther., 10, 1, 10.1038/sj.cgt.7700527

Tong, 2001, Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer, Clin. Cancer Res., 7, 691

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J. Clin. Invest., 1, 1

Yadav, 2014, Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing, Nature, 515, 572, 10.1038/nature14001

Yeku, 2017, Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment, Sci. Rep., 7, 10541, 10.1038/s41598-017-10940-8

Zhao, 2015, Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells, Cancer Cell, 28, 415, 10.1016/j.ccell.2015.09.004